Trials / Completed
CompletedNCT01908712
Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients
A Multi-center, Un-controlled, Open-labeled Trial of the Long-term Safety of Lamazym Aftercare Treatment of Subjects With Alpha-Mannosidosis Whom Previously Participated in Lamazym Trials
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Chiesi Farmaceutici S.p.A. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The overall objective of this trial is to provide aftercare treatment with Lamazym and to evaluate the safety of repeated Lamzede i.v. treatment of subjects with alpha-Mannosidosis.
Detailed description
This trial provide aftercare treatment with Lamzede to French patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lamazym | ERT, i.v. infusions weekly |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2022-09-30
- Completion
- 2022-09-30
- First posted
- 2013-07-26
- Last updated
- 2023-07-28
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01908712. Inclusion in this directory is not an endorsement.